Environmental, Social And Governance Report

Overview

The report is the Group’s ninth ESG report and highlights the 2025 approval of its new ophthalmic drug Jinyinkang. It provides expanded Scope 1, 2 and 3 emissions disclosures alongside detailed energy, water and waste KPIs. The Group reports zero work-related fatalities during the reporting year.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services